Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days

Kandice Knigge, C. Kelly, W. L. Peterson, M (Brian) Fennerty

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: We assessed the efficacy, tolerance, and compliance of twice-daily triple therapy for Helicobacter pylori with ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days. Methods: 105 subjects with H, pylori infection documented by the 13C-urea breath test were randomly assigned to a 7 or 10-day course of ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d. Subjects returned at the end of therapy for assessment of side-effects and pill count. A repeat 13C-urea breath test was obtained 4 or more weeks after completion of therapy and cure of infection was defined as a negative test result. Results: Poor compliance (<80% of medications) was seen in 2% of subjects randomized to 7 days of therapy and in 10% randomized to 10 days of therapy (P = N.S.). Intention-to-treat eradication rates were 56% for 7-day and 60% for 10-day therapy (P = N.S.). Per protocol eradication rates were 58% for 7-day and 61% for 10-day therapy (P = N.S.). The 10-day intention-to-treat eradication rate for males was 78% and 32% for females (P <0.01) and per protocol eradication rates were 79% and 31%, respectively (P <0.01). Conclusions: Despite excellent compliance and tolerance, neither 7 nor 10 days of therapy with twice-daily ranitidine bismuth citrate, metronidazole and tetracycline are adequate as a treatment of H. pylori infection.

Original languageEnglish (US)
Pages (from-to)323-326
Number of pages4
JournalAlimentary Pharmacology and Therapeutics
Volume13
Issue number3
DOIs
StatePublished - 1999

Fingerprint

Metronidazole
Helicobacter Infections
Tetracycline
Helicobacter pylori
Breath Tests
Therapeutics
Compliance
Urea
ranitidine bismuth citrate
Pylorus
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days. / Knigge, Kandice; Kelly, C.; Peterson, W. L.; Fennerty, M (Brian).

In: Alimentary Pharmacology and Therapeutics, Vol. 13, No. 3, 1999, p. 323-326.

Research output: Contribution to journalArticle

@article{bf0363af384b4ac6a798fc4287ad633a,
title = "Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days",
abstract = "Background: We assessed the efficacy, tolerance, and compliance of twice-daily triple therapy for Helicobacter pylori with ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days. Methods: 105 subjects with H, pylori infection documented by the 13C-urea breath test were randomly assigned to a 7 or 10-day course of ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d. Subjects returned at the end of therapy for assessment of side-effects and pill count. A repeat 13C-urea breath test was obtained 4 or more weeks after completion of therapy and cure of infection was defined as a negative test result. Results: Poor compliance (<80{\%} of medications) was seen in 2{\%} of subjects randomized to 7 days of therapy and in 10{\%} randomized to 10 days of therapy (P = N.S.). Intention-to-treat eradication rates were 56{\%} for 7-day and 60{\%} for 10-day therapy (P = N.S.). Per protocol eradication rates were 58{\%} for 7-day and 61{\%} for 10-day therapy (P = N.S.). The 10-day intention-to-treat eradication rate for males was 78{\%} and 32{\%} for females (P <0.01) and per protocol eradication rates were 79{\%} and 31{\%}, respectively (P <0.01). Conclusions: Despite excellent compliance and tolerance, neither 7 nor 10 days of therapy with twice-daily ranitidine bismuth citrate, metronidazole and tetracycline are adequate as a treatment of H. pylori infection.",
author = "Kandice Knigge and C. Kelly and Peterson, {W. L.} and Fennerty, {M (Brian)}",
year = "1999",
doi = "10.1046/j.1365-2036.1999.00485.x",
language = "English (US)",
volume = "13",
pages = "323--326",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days

AU - Knigge, Kandice

AU - Kelly, C.

AU - Peterson, W. L.

AU - Fennerty, M (Brian)

PY - 1999

Y1 - 1999

N2 - Background: We assessed the efficacy, tolerance, and compliance of twice-daily triple therapy for Helicobacter pylori with ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days. Methods: 105 subjects with H, pylori infection documented by the 13C-urea breath test were randomly assigned to a 7 or 10-day course of ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d. Subjects returned at the end of therapy for assessment of side-effects and pill count. A repeat 13C-urea breath test was obtained 4 or more weeks after completion of therapy and cure of infection was defined as a negative test result. Results: Poor compliance (<80% of medications) was seen in 2% of subjects randomized to 7 days of therapy and in 10% randomized to 10 days of therapy (P = N.S.). Intention-to-treat eradication rates were 56% for 7-day and 60% for 10-day therapy (P = N.S.). Per protocol eradication rates were 58% for 7-day and 61% for 10-day therapy (P = N.S.). The 10-day intention-to-treat eradication rate for males was 78% and 32% for females (P <0.01) and per protocol eradication rates were 79% and 31%, respectively (P <0.01). Conclusions: Despite excellent compliance and tolerance, neither 7 nor 10 days of therapy with twice-daily ranitidine bismuth citrate, metronidazole and tetracycline are adequate as a treatment of H. pylori infection.

AB - Background: We assessed the efficacy, tolerance, and compliance of twice-daily triple therapy for Helicobacter pylori with ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days. Methods: 105 subjects with H, pylori infection documented by the 13C-urea breath test were randomly assigned to a 7 or 10-day course of ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d. Subjects returned at the end of therapy for assessment of side-effects and pill count. A repeat 13C-urea breath test was obtained 4 or more weeks after completion of therapy and cure of infection was defined as a negative test result. Results: Poor compliance (<80% of medications) was seen in 2% of subjects randomized to 7 days of therapy and in 10% randomized to 10 days of therapy (P = N.S.). Intention-to-treat eradication rates were 56% for 7-day and 60% for 10-day therapy (P = N.S.). Per protocol eradication rates were 58% for 7-day and 61% for 10-day therapy (P = N.S.). The 10-day intention-to-treat eradication rate for males was 78% and 32% for females (P <0.01) and per protocol eradication rates were 79% and 31%, respectively (P <0.01). Conclusions: Despite excellent compliance and tolerance, neither 7 nor 10 days of therapy with twice-daily ranitidine bismuth citrate, metronidazole and tetracycline are adequate as a treatment of H. pylori infection.

UR - http://www.scopus.com/inward/record.url?scp=0033002159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033002159&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.1999.00485.x

DO - 10.1046/j.1365-2036.1999.00485.x

M3 - Article

C2 - 10102965

AN - SCOPUS:0033002159

VL - 13

SP - 323

EP - 326

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -